AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary artery disease (CAD).

Diversify Wealth Management LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.6% during the ...

Ameritas Advisory Services LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 25.9% during the fourth quarter, according to the company in its most recent disclosure ...

May 2017 – Outcomes-based agreements with AstraZeneca for Brilinta (ticagrelor) and Bydurean (exenatide extended-release) to treat acute coronary disease and type II diabetes respectively.

AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...

AstraZeneca PLC AZN-Q is investing $820-million and creating more than 700 jobs in Ontario’s life sciences industry, stimulating growth within a national research and development sector that has ...

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 17,321.50 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...